Roberto Badagliacca
A5007480230- Pulmonary Hypertension Research and Treatments
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiovascular Issues in Pregnancy
- Mechanical Circulatory Support Devices
- Cardiovascular and exercise physiology
- Cardiac Structural Anomalies and Repair
- Congenital Heart Disease Studies
- Cardiac Valve Diseases and Treatments
- Cardiovascular Effects of Exercise
- Cardiac pacing and defibrillation studies
- Vascular Anomalies and Treatments
- Cardiac Arrhythmias and Treatments
- Liver Disease and Transplantation
- Diabetes Treatment and Management
- Hemodynamic Monitoring and Therapy
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Cardiac Health and Mental Health
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Atrial Fibrillation Management and Outcomes
- Systemic Sclerosis and Related Diseases
- Cardiac Arrest and Resuscitation
- Heart Rate Variability and Autonomic Control
Sapienza University of Rome
2016-2025
Policlinico Umberto I
2015-2025
Ospedale Cisanello
2024
RELX Group (United States)
2024
University of Strathclyde
2022
Ospedale di Santo Spirito
2022
Istituti Clinici Scientifici Maugeri
2022
European Society of Hypertension
2020
Erasmus Hospital
2017
Respiratory Clinical Trials
2014
2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations focusing on clinical management https://bit.ly/3QtUvb4
Background— The prognostic significance of syncope has not been investigated systematically in hypertrophic cardiomyopathy, and treatment strategies have based largely on intuition experience. Methods Results— We assessed the relationship between sudden death 1511 consecutive patients with cardiomyopathy. Unexplained (n=153) or neurally mediated (n=52) occurred 205 (14%). Over a 5.6±5.2-year follow-up, 74 died suddenly. Relative risk was 1.78 (95% confidence interval 0.88 to 3.51, P =0.08)...
Worsening heart failure (WHF) is a severe and dynamic condition characterized by significant clinical hemodynamic deterioration. It worsening HF signs, symptoms biomarkers, despite the achievement of an optimized medical therapy. remains challenge in cardiology, as it evolves into advanced end-stage HF. The hyperactivation neurohormonal, adrenergic renin-angiotensin-aldosterone system are well known pathophysiological pathways involved Several drugs have been developed to inhibit latter,...
Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars heart failure (HF) pharmacological therapy. The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF reduced ejection fraction (HFrEF) in terms atrial and ventricular arrhythmias (AAs VAs) reduction. HFrEF carriers implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT-D) followed by remote monitoring Policlinico Umberto I Rome for 1 year before after...
The aim of this study was to determine the prevalence right intraventricular dyssynchrony, its determinants and prognostic impact in idiopathic, heritable, anorexigen-induced pulmonary arterial hypertension.Right ventricular dyssynchrony has been described hypertension, but no evidence is available on evolution after therapy.In 83 consecutive therapy-naïve patients, evaluated by 2-dimensional speckle-tracking echocardiography calculating standard deviation times peak-systolic strain for 4...
Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition.Which factors determine the outcome of PH COPD?We analyzed characteristics and patients enrolled Comparative, Prospective Registry Newly Initiated Therapies for Hypertension (COMPERA) with moderate or severe as defined during 6th World Symposium who received medical therapy compared them idiopathic pulmonary arterial (IPAH).The population included incident (n = 68), 307), IPAH 489). Patients were older,...
Objective. Pulmonary arterial hypertension (PAH) is a complication of SSc due to increased vascular resistance, and abnormal vascularity well-known feature the disease as shown by nailfold videocapillaroscopy (NVC). This study investigated for specific NVC changes in patients with without PAH assess any useful difference. Methods. Twenty-four patients, 12 without, entered study. Evidence was defined systolic pulmonary artery pressure (PAP) (≥35 mmHg), indirectly assessed echocardiography...
Rationale: An initial oral combination of drugs is being recommended in pulmonary arterial hypertension (PAH), but the effects this approach on risk reduction and vascular resistance (PVR) are not known.Objectives: To test hypothesis that a low-risk status would be determined by PVR patients with PAH treated upfront drugs.Methods: The study enrolled 181 treatment-naive (81% idiopathic) follow-up right heart catheterization at 6 months (interquartile range, 144–363 d) after endothelin...
Section:ChooseTop of pageAbstract <<The Pathophysiology RV...Clinical Importance RV...Effect PAH Therapies o...RV Morphology, Function, ...Open Questions and IssuesConclusionsOptimizing Knowledge: Cal...ReferencesCITING ARTICLES
Cyclic GMP–phosphodiesterase type 5 (PDE5) inhibition has been shown to counteract maladaptive cardiac changes triggered by diabetes in some but not all studies. We performed a single-center, 20-week, double-blind, randomized, placebo-controlled trial (NCT01803828) assess sex differences remodeling after PDE5 patients with diabetic cardiomyopathy. A total of 122 men and women (45 80 years) long-duration (>3 well-controlled 2 mellitus (T2DM; HbA1c < 86 mmol/mol) were selected according...
Proper therapeutic management of patients with heart failure (HF) is a major challenge for cardiologists. Current guidelines indicate to start therapy angiotensin converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors (ACEi/ARNI), beta blockers (BB), mineralocorticoid antagonists (MRAs) and sodium glucose cotransporter 2 (SGLT2i) reduce the risk death hospitalization due HF. However, certain aspects still need be defined. propose algorithms based on left ventricular ejection...